Tuesday, October 26, 2021 6:51:22 PM
For example, if you ever bought a house.
You prequalify to get a loan. Then when you go through all the process for closing the underwriters (the WHO) come back and say your missing a few items they give you a list of what they are looking for to satisfy the loan. You go back and gather all the info requested and return with everything they asked for. BOOM Loan approved.
That’s where we are with Covaxin right now. They gave us the blueprint to get the approved. Nothing else to do but wait for approval.
Recent OCGN News
- Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/03/2024 11:30:05 AM
- Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress • GlobeNewswire Inc. • 05/02/2024 11:15:46 AM
- Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024 • GlobeNewswire Inc. • 04/29/2024 10:45:00 AM
- UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting • GlobeNewswire Inc. • 04/26/2024 01:05:24 PM
- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting • GlobeNewswire Inc. • 04/26/2024 10:30:40 AM
- Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy • GlobeNewswire Inc. • 04/19/2024 11:13:05 AM
- Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets • GlobeNewswire Inc. • 04/12/2024 11:30:34 AM
- Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication • GlobeNewswire Inc. • 04/10/2024 11:02:26 AM
- Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication • GlobeNewswire Inc. • 04/08/2024 10:30:43 AM
- Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy • GlobeNewswire Inc. • 04/05/2024 11:02:21 AM
- Ocugen Provides Business Update with Certain Financials for the Year Ending 2023 • GlobeNewswire Inc. • 04/02/2024 12:00:39 PM
- Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease • GlobeNewswire Inc. • 04/01/2024 10:08:46 PM
- Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023 • GlobeNewswire Inc. • 04/01/2024 09:43:45 PM
- Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer • GlobeNewswire Inc. • 03/18/2024 10:30:50 AM
- Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410 • GlobeNewswire Inc. • 03/13/2024 12:00:54 PM
- Ocugen to Present at Investing in Cures Summit • GlobeNewswire Inc. • 03/06/2024 12:30:09 PM
- Ocugen Clinical Showcase Webcast Now Available • GlobeNewswire Inc. • 02/28/2024 01:00:26 PM
- Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit • GlobeNewswire Inc. • 02/26/2024 01:30:13 PM
- Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST • GlobeNewswire Inc. • 02/22/2024 09:05:00 PM
- Ocugen to Present at 2024 BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/21/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 04:22:29 PM
- Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024 • GlobeNewswire Inc. • 02/14/2024 12:30:49 PM
- Ocugen to Present at Pharma Market Research Conference • GlobeNewswire Inc. • 01/31/2024 01:00:12 PM
- Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board • GlobeNewswire Inc. • 01/16/2024 12:30:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 11:05:28 AM
FEATURED Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • May 8, 2024 9:05 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • BLOZF • May 7, 2024 8:51 AM